MPM
NVO

Meritage Portfolio Management’s Novo Nordisk NVO Stock Holding History

Meritage Portfolio Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,819
Closed -$212K – 333
2025
Q3 		$212K Sell
3,819
-148,831
-97% -$8.71M 0.01% 314
2025
Q2 		$10.5M Sell
152,650
-41,042
-21% -$2.79M 0.67% 36
2025
Q1 		$13.4M Sell
193,692
-5,395
-3% -$446K 0.89% 27
2024
Q4 		$17.1M Sell
199,087
-4,706
-2% -$509K 1.06% 15
2024
Q3 		$24.3M Sell
203,793
-2,230
-1% -$297K 1.49% 9
2024
Q2 		$29.4M Sell
206,023
-33,177
-14% -$4.4M 1.86% 6
2024
Q1 		$30.7M Sell
239,200
-9,859
-4% -$1.17M 1.96% 6
2023
Q4 		$25.8M Buy
249,059
+16,159
+7% +$1.6M 1.7% 5
2023
Q3 		$21.2M Buy
232,900
+256
+0.1% +$22.6K 1.56% 6
2023
Q2 		$18.8M Buy
232,644
+131,016
+129% +$10.7M 1.33% 10
2023
Q1 		$8.09M Buy
+101,628
New +$7.21M 0.61% 40
2022
Q1 		– Sell
-131,550
Closed -$7.37M – 372
2021
Q4 		$7.37M Buy
131,550
+1,710
+1% +$92.6K 0.42% 63
2021
Q3 		$6.23M Buy
129,840
+1,208
+0.9% +$58.4K 0.37% 72
2021
Q2 		$5.39M Buy
128,632
+3,410
+3% +$132K 0.32% 91
2021
Q1 		$4.22M Buy
125,222
+21,410
+21% +$763K 0.28% 110
2020
Q4 		$3.63M Buy
103,812
+6,364
+7% +$220K 0.27% 95
2020
Q3 		$3.38M Buy
97,448
+622
+0.6% +$20.7K 0.3% 80
2020
Q2 		$3.17M Sell
96,826
-2,778
-3% -$88.6K 0.3% 91
2020
Q1 		$3M Sell
99,604
-4,602
-4% -$137K 0.41% 72
2019
Q4 		$3.02M Sell
104,206
-1,580
-1% -$43.7K 0.27% 129
2019
Q3 		$2.73M Buy
105,786
+11,908
+13% +$301K 0.26% 139
2019
Q2 		$2.4M Buy
+93,878
New +$2.32M 0.24% 126
2014
Q3 		– Sell
-342,500
Closed -$7.91M – 210
2014
Q2 		$7.91M Buy
342,500
+4,500
+1% +$99.4K 0.86% 13
2014
Q1 		$7.71M Buy
338,000
+5,410
+2% +$115K 0.93% 13
2013
Q4 		$6.14M Sell
332,590
-16,600
-5% -$289K 0.76% 32
2013
Q3 		$5.91M Sell
349,190
-169,480
-33% -$2.85M 0.77% 30
2013
Q2 		$8.04M Buy
+518,670
New +$8.63M 1.15% 8

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Meritage Portfolio Management's NVO Position: Q4 2025 in Review

Meritage Portfolio Management sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 3,819 shares — an estimated $212K sold.

Meritage Portfolio Management first reported a position in NVO in Q2 2013 and held it in 27 quarters. The position peaked at $30.7M in Q1 2024. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Meritage Portfolio Management reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Meritage Portfolio Management sold 3,819 Novo Nordisk shares in Q4 2025, an estimated $212K.
  • Meritage Portfolio Management first reported a position in Novo Nordisk in Q2 2013 and held it in 27 quarters.
  • Meritage Portfolio Management's Novo Nordisk position peaked at $30.7M in Q1 2024.
  • 1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Meritage Portfolio Management's 13F filing for Q4 2025, filed 27 Jan 2026.